Linda Rossi-Semerano

Summary

Country: France

Publications

  1. doi request reprint Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
    Linda Rossi-Semerano
    Department of Paediatric Rheumatology, Hopital de Bicetre, APHP, National Reference Centre for Auto Inflammatory Diseases, Le Kremlin Bicetre, University of Paris Sud, CHU de Bicêtre 78 Rue du Général Leclerc, 94270, Le Kremlin, Bicetre, France
    Orphanet J Rare Dis 10:19. 2015
  2. pmc The expanding spectrum of rare monogenic autoinflammatory diseases
    Isabelle Touitou
    Laboratoire de génétique des maladies rares et auto inflammatoires, CHRU de Montpellier, Montpellier, France
    Orphanet J Rare Dis 8:162. 2013
  3. pmc Is Still's Disease an Autoinflammatory Syndrome?
    Linda Rossi-Semerano
    Department of Paediatrics and Paediatric Rheumatology, Bicetre Hospital, National Reference Centre for Autoinflammatory Diseases, 78 rue du General Leclerc, Le Kremlin Bicetre, 94270 Paris, France
    Int J Inflam 2012:480373. 2012
  4. doi request reprint First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra
    Linda Rossi-Semerano
    Department of Pediatrics and Pediatric Rheumatology, National Reference Centre for Auto Inflammatory Diseases, University of Paris Sud, APHP, Hopital de Bicetre, 78, rue du Général Leclerc 94275 Le Kremlin Bicêtre cedex, France
    Pediatrics 132:e1043-7. 2013
  5. pmc The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients
    Jerome Stirnemann
    INSERM, UMR 738, Laboratoire de Biostatistiques Hôpital Bichat, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Orphanet J Rare Dis 7:77. 2012
  6. ncbi request reprint Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency
    Caroline Galeotti
    Department of Pediatrics and Pediatric Rheumatology, National Referral Centre of Auto inflammatory Diseases, CEREMAI, CHU Bicetre, Assistance Publique Hopitaux de Paris, University of Paris Sud, Le Kremlin Bicetre, France
    Rheumatology (Oxford) 51:1855-9. 2012

Collaborators

  • Isabelle Kone-Paut
  • Eric Hachulla
  • Pierre Quartier
  • Luca Semerano
  • Daniel Wendling
  • Caroline Galeotti
  • Isabelle Touitou
  • Jerome Stirnemann
  • Maryam Piram
  • Véronique Hentgen
  • Ulrich Meinzer
  • Brigitte Bader-Meunier
  • France Mentre
  • Catherine Caillaud
  • Olivier Fain
  • Pierre Kaminsky
  • Roselyne Froissart
  • Djazia Heraoui
  • Vassili Valayanopoulos
  • Nadia Belmatoug
  • Marc G Berger
  • Dries Dobbelaere
  • Dalil Hamroun
  • Alain Robert
  • Frédéric Sedel
  • Bernard Grosbois
  • Thierry Billette de Villemeur
  • Christian Rose
  • Bruno Fantin
  • Marie Vigan
  • Thierry Levade
  • Christine de Roux-Serratrice
  • Agathe Masseau
  • Marie T Vanier
  • Fabrice Camou
  • Cyril Mignot
  • Pascal Pillet

Detail Information

Publications6

  1. doi request reprint Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey
    Linda Rossi-Semerano
    Department of Paediatric Rheumatology, Hopital de Bicetre, APHP, National Reference Centre for Auto Inflammatory Diseases, Le Kremlin Bicetre, University of Paris Sud, CHU de Bicêtre 78 Rue du Général Leclerc, 94270, Le Kremlin, Bicetre, France
    Orphanet J Rare Dis 10:19. 2015
    ..We aimed to estimate the off-label use of anti-IL-1 treatments in France, assess their efficacy in rare diseases, and increase the reporting of their possible side effects...
  2. pmc The expanding spectrum of rare monogenic autoinflammatory diseases
    Isabelle Touitou
    Laboratoire de génétique des maladies rares et auto inflammatoires, CHRU de Montpellier, Montpellier, France
    Orphanet J Rare Dis 8:162. 2013
    ..We believe that this update will assist physicians in correctly naming their patient's illness. This is an essential step for the effective and targeted management of an orphan disease. ..
  3. pmc Is Still's Disease an Autoinflammatory Syndrome?
    Linda Rossi-Semerano
    Department of Paediatrics and Paediatric Rheumatology, Bicetre Hospital, National Reference Centre for Autoinflammatory Diseases, 78 rue du General Leclerc, Le Kremlin Bicetre, 94270 Paris, France
    Int J Inflam 2012:480373. 2012
    ..The new insights on the pathogenesis of sJIA have therefore dramatically changed the approach to treatment, with the development of targeted treatments (anti-IL-1 and anti-IL-6 agents) more effective and safer than earlier medications...
  4. doi request reprint First clinical description of an infant with interleukin-36-receptor antagonist deficiency successfully treated with anakinra
    Linda Rossi-Semerano
    Department of Pediatrics and Pediatric Rheumatology, National Reference Centre for Auto Inflammatory Diseases, University of Paris Sud, APHP, Hopital de Bicetre, 78, rue du Général Leclerc 94275 Le Kremlin Bicêtre cedex, France
    Pediatrics 132:e1043-7. 2013
    ..We report herein the first exhaustive clinical description of an infant with DITRA who was successfully treated with anakinra. ..
  5. pmc The French Gaucher's disease registry: clinical characteristics, complications and treatment of 562 patients
    Jerome Stirnemann
    INSERM, UMR 738, Laboratoire de Biostatistiques Hôpital Bichat, Assistance Publique Hopitaux de Paris AP HP, Paris, France
    Orphanet J Rare Dis 7:77. 2012
    ..Clinical features, complications and treatments of Gaucher's disease (GD), a rare autosomal-recessive disorder due to a confirmed lysosomal enzyme (glucocerebrosidase) deficiency, are described...
  6. ncbi request reprint Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency
    Caroline Galeotti
    Department of Pediatrics and Pediatric Rheumatology, National Referral Centre of Auto inflammatory Diseases, CEREMAI, CHU Bicetre, Assistance Publique Hopitaux de Paris, University of Paris Sud, Le Kremlin Bicetre, France
    Rheumatology (Oxford) 51:1855-9. 2012
    ..To describe the efficacy and safety of IL-1-targeting drugs, anakinra and canakinumab, in patients with mevalonate kinase deficiency (MKD)...